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Abstract
Filarial nematodes enjoy one of the longest life spans of any human pathogen due to effective immune evasion strategies
developed by the parasite. Among the various immune evasion strategies exhibited by the parasite, Interleukin 10 (IL-10)
productions and IL-10 mediated immune suppression has significant negative impact on the host immune system. Recently,
we identified a small heat shock protein expressed by Brugia malayi (BmHsp12.6) that can bind to soluble human IL-10
receptor alpha (IL-10R) and activate IL-10 mediated effects in cell lines. In this study we show that the IL-10R binding region
of BmHsp12.6 is localized to its N-terminal region. This region has significant sequence similarity to the receptor binding
region of human IL-10. In vitro studies confirm that the N-terminal region of BmHsp12.6 (N-BmHsp12.6) has IL-10 like activity
and the region containing the alpha crystalline domain and C-terminus of BmHsp12.6 (BmHsp12.6ac) has no IL-10 like
activity. However, BmHsp12.6ac contains B cell, T cell and CTL epitopes. Members of the sHSP families are excellent vaccine
candidates. Evaluation of sera samples from putatively immune endemic normal (EN) subjects showed IgG1 and IgG3
antibodies against BmHsp12.6ac and these antibodies were involved in the ADCC mediated protection. Subsequent
vaccination trials with BmHsp12.6ac in a mouse model using a heterologous prime boost approach showed that 83%
protection can be achieved against B. malayi L3 challenge. Results presented in this study thus show that the N-BmHsp12.6
subunit of BmHsp12.6 has immunoregulatory function, whereas, the BmHsp12.6ac subunit of BmHsp12.6 has significant
vaccine potential.
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Introduction
Lymphatic filariasis caused by the filarial nematodes Wuchereria
bancrofti, Brugia malayi, and Brugia timori affects more than 120
million people worldwide [1]. Mass drug administration program
by the World Health Organization, significantly reduced the
incidence rate of lymphatic filariasis in many parts of the world
[2]. However, additional approaches such as use of a vaccine can
speed up the effort to eradicate the infection from endemic
regions. There are no effective vaccines currently available to
control this infection although several candidate vaccine antigens
have been reported by several groups including our laboratory
[3,4,5].
Lymphatic filarial parasites evade the primary line of defense at
the skin site and migrate to the lymphatics, where they develop
into mature adults and produce microfilariae that are released into
the circulation. Individuals with active filarial infection and
circulating microfilariae show peripheral blood T-cell hypo
responsiveness have poor Th1 type responses and produce high
levels of spontaneous IL-10 [6,7,8]. This spontaneous production
of IL-10 appears to be parasite mediated [9]. In one of our
previous studies [10] when we screened a phage display cDNA
expression library of B. malayi L3 with IL-10R we identified small
heat shock protein 12.6 kDa of B. malayi (BmHsp12.6) as an IL-
10R binding protein. However, we did not identify the peptide
sequence of BmHsp12.6 that binds to IL-10R. Nevertheless, our
studies showed that rBmHsp12.6 can induce IL-10-like prolifer-
ative effects in vitro in MC/9 cell lines [10]. In the present study we
mapped the IL-10R binding region of BmHsp12.6 and evaluated
if this binding region has IL-10 like activity.
The small heat shock proteins (HSP) are a diverse family of 12–
43 kDa proteins that assemble into large multimeric structures and
functions as chaperone by preventing protein aggregation. Small
HSPs contain a conserved a-crystalline domain that is important
for its chaperone function [11]. Since BmHsp12.6 also contains a-
crystalline domain, in this study we tested if rBmHsp12.6 has
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34077chaperone like function. Other reported properties of small HSPs
include inhibition of apoptosis [12], actin polymerization and
contribution to the optical properties of the eye lens [13].
Transcriptome analysis on B. malayi L3 showed that small HSPs
are upregulated during the transition of L3 from mosquitoes into
mammalian hosts [14]. Thus, when the B. malayi pathogen enters
the mammalian host, the stress imposed by the host might lead to
increased BmHsp12.6 synthesis. Given the chaperone activity of
HSPs, these upregulated BmHsp12.6 can protect the parasite
proteins from damage. Another potential function of the
upregulated BmHsp12.6 could be to modulate host immune
responses, as BmHsp12.6 has IL-10 like function. This in turn can
suppress the immune response initially and help establish the
infection in the host. Recently, Wolbachia HSP60 was identified to
contribute to the immune modulation seen in filarial patients [15].
Therefore, BmHsp12.6 appears to be a critical molecule for
survival of the parasite in the host. Given its potential
immunoregulatory role, BmHsp12.6 is also an attractive target
for developing a vaccine against B. malayi. HSP-based vaccines
have been successfully developed against tuberculosis [16,17],
cancers [18] and against various infectious agents [19–21].
Immunization of mice with recombinant HSP60 conferred
protection against Histoplasma capsulatum [22] and Porphyromonas
gingivalis [23]. Thus, HSP appears to be a good vaccine candidate.
Interestingly, HSP is also shown to be an excellent vehicle for
vaccine development [15,22]. Antigens genetically fused to hsp70
were shown to elicit strong and long-lived humoral and cellular
immune responses in the absence of adjuvant [24]. Epitope
analysis on the BmHsp12.6 showed that it contains several
potential T cell, B cell and CTL epitopes. Therefore, in this study
we evaluated the vaccine potential of BmHsp12.6 and its subunits
against B. malayi in a mouse model.
Methods
Ethics Statement
Use of human subjects in this study was approved by the IRB
committees at Department of Biochemistry, Mahatma Gandhi
Institute of Medical Sciences, Sevagram, India and at the
University of Illinois, Rockford, USA. Informed written consent
in native language was obtained from all the subjects before
collecting the samples.
Humane use of animals was performed in this study according
to the guidelines for the care and use of laboratory animals and
with the rules formulated under the Animal Welfare Act by the
U.S. Department of Agriculture. The protocol was approved by
the IACUC Committee of the University of Illinois, College of
Medicine at Rockford and performed at a facility accredited by
AAALAC and USDA.
Parasites
Brugia malayi L3 were obtained from the NIAID/NIH Filariasis
Research Reagent Resource Center (FR3) at the University of
Georgia, Athens, GA.
Human sera Samples
Blood samples were collected after taking informed consent
from clinically diagnosed filarial patients and from healthy adult
individuals residing in Sevagram and surrounding villages in
Maharastra State, which are non-coastal endemic areas for
nocturnally periodic W. bancrofti infection. Samples were also
collected from volunteers who live in areas that are non endemic
for filariasis. Parasitological examination of all individuals was
done by detection of microfilariae in night blood smears. The
presence of mf was further confirmed by membrane (Millipore-
5 m filters) filtration of 1.0 ml of heparinized venous blood [25].
The presence of circulating antigen was detected using a WbSXP
based enzyme-linked immunosorbent assay (ELISA) [26]. About
10 ml of blood samples (5 ml in heparinized tubes) were collected
from the following clinical groups of subjects (a) Endemic normal
(EN) subjects, these are individuals who are asymptomatic and
non-microfilaraemic residing in Sevagram (b) Asymptomtic
microfilaraemic subjects (MF) were classified based on the
presence of circulating mf in blood. (c) Chronic Pathology (CP)
patients include those subjects who exhibit lymph edema and
other chronic clinical symptoms of filariasis. These CP patients did
not carry circulating mf and (d) Non-endemic normal (NEN)
subjects who live in non-endemic areas and have no circulating
parasites or antibodies and show no evidence of any clinical
lymphatic filarial disease. These are healthy volunteers from
filariasis free regions in India such as Chandigarh, Haryana,
Punjab and Kashmir. Sera were separated from these blood
samples and were stored at 280uC until use.
Expression and purification of recombinant Brugia malayi
heat shock protein
Recombinant B. malayi small heat shock protein 12.6 kDa
(rBmHsp12.6) was expressed and purified using an immobilized
cobalt metal affinity column chromatography as described earlier
[10]. Briefly, the full-length gene sequence of BmHsp12.6 was
cloned into pRSET-A vector (with an N-terminal hexahistidine
tag) and transformed into BL21(DE3) containing pLysS (Invitro-
gen, Carlsbad, CA) to minimize toxicity due to the protein. When
absorbance of the cultures reached 0.6 OD value, 1 mM of IPTG
(isopropyl thio-d-galacto pyranoside) was added to the cultures and
incubated for an additional 3 hours to induce gene expression.
The histidine tagged recombinant protein was purified using an
immobilized cobalt metal affinity column chromatography
(Clontech, Mountain View, CA) as per manufacturer’s recom-
mendations. Recombinant protein separated in a 15% SDS-
PAGE and stained with coomassie brilliant blue R250 showed a
single band (data not shown). After purification, rBmHsp12.6
protein was passed through polymyxin B columns (Thermo Fisher,
Rockford, IL) to remove any contaminating endotoxin. Levels of
endotoxin in the final recombinant protein preparation were
confirmed by LAL assay (Gen Script, Piscataway, NJ) and were
found to be below 1 IU/ml.
Structure and motif analysis on BmHsp12.6
Analysis of the secondary structure and protein-protein
interaction site of BmHsp12.6 was predicted at PDBsum and at
the Predict Protein E-mail server at the European Molecular
Biology Laboratory [EMBL], Heidelberg, as described by Rost et
al [27]. Motif scanning was done using PROSITE pattern analysis
to identify the functional motifs in BmHsp12.6.
Chaperone assay
Chaperones can bind to cellular proteins and protect them from
heat damage. When proteins are exposed to heat damage, they
aggregate (thermal aggregation) and chaperones can prevent this
thermal aggregation. To determine if BmHsp12.6 can prevent
thermal aggregation, we used citruline synthase (CS) (Sigma, St.
Louis, MO) as a substrate protein to induce thermal aggregation.
CS was selected because this protein is a natural cellular protein
and is highly sensitive to heat denaturation. Thermal aggregation
assay was performed as described previously from our laboratory
[28]. Briefly, 1 mM of CS was exposed to 45uC in the presence or
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phosphate pH 7.4 buffer containing 100 mM NaCl. BSA was used
as a control. CS was incubated with BmHsp12.6 at a molar ratio
of 1:2 for various time intervals from 0 to 40 minutes. Thermal
denaturation (aggregation) was monitored spectrophotometrically
at 300 nm.
In vitro peptide binding assay for chaperone activity
Chaperons can bind to denatured proteins. To test if BmHsp12.6
can also bind to denatured proteins, we chemically denatured CS
and another protein, luciferase (LUC) with 6 M guanidine
hydrochloride overnight at 4uC as described previously [28]. Native
and chemically denatured proteins were then coated on to 96 well
plates overnight at 4uC. After washing with PBS, wells were blocked
with 3% BSA at room temperature. Following further washing,
wells were incubated with his tag rBmHsp12.6 or control filarial
protein (his tag abundant larval transcript-2) for 1 hr at 37uC. After
washing with PBS, optimally diluted anti-his tag HRP conjugate
was added and incubated at 37uC for 1 hr. After final washing,
color was developed with OPD (o-phenylenediamine dihydrochlo-
ride) substrate and OD was measured at 450 nm.
Epitope mapping on BmHsp12.6
B-cell epitopes, T- cell epitopes and CTL epitopes on
BmHsp12.6 sequences were predicted using Immune Epitope
Database and Analysis Resource (IEDB) at http: // epitope2.
immuneepitope.org /home. do. Propred [29] tool was also used for
prediction of HLA binding peptides, to identify putative T epitopes.
Peptide synthesis
Two peptide fragments of BmHsp12.6; N-BmHsp12.6 (aa 1–36)
and BmHsp12.6ac (aa 61–113) were synthesized chemically at
Genescript Corporation.
Assay to determine IL-10-like function
BmHsp12.6 binds to huIL-10R and induces IL-10-like function
[10]. To determine if the huIL-10R binding peptide of
BmHsp12.6 is involved in the IL-10-like function, we used an
IL-10 dependent MC/9 cell proliferative assay as described
previously [10]. Briefly, the mast cell line, MC/9 (ATCC,
Manassas, VA) was maintained in DMEM supplemented with
10% FBS, 0.05 mM 2-ME, and 10% Rat T-STIM (Becton
Dickenson, San Jose, CA) at 37uCi n5 %C O 2 environment.
About 5610
3 MC/9 mast cells were suspended in DMEM
containing IL-3 (10 ng/ml), IL-4 (10 ng/ml) and polymyxin B
(10 mg/ml) and plated on a flat bottomed 96 well tissue culture
plates and stimulated with 10 mg/ml of N-BmHsp12.6 peptide or
BmHsp12.6ac peptide or rBmHsp12.6 protein. Recombinant
huIL-10 (100 ng/ml) was used as a positive control. In some wells
polyclonal antibodies against N-BmHsp12.6 or BmHsp12.6ac
peptides (50 ml) was added along with the peptides or proteins to
block the function of respective proteins. Sera from control Balb/c
mice was used as a negative control in the inhibition studies. After
72 h of culture, cell proliferation was determined using a cell
proliferation kit purchased from Dojindo Molecular Technologies
Inc., Gaithersburg, MA.
Anti-BmHsp12.6 antibody levels in human sera
Sera samples from 20 MF, CP, EN or NEN subjects were
analyzed for the presence and titer of IgG antibodies against
rBmHsp12.6 and its peptides using an indirect ELISA as described
previously [5]. Briefly, wells of a 96 well microtitre plate were
coated with rBmHsp12.6 (1 mg/ml), N-BmHsp12.6 peptide (5 mg/
ml) or BmHsp12.6ac peptide (5 mg/ml) in carbonate buffer,
pH 9.6 overnight at 4uC and blocked with 3% BSA for 1 h at
37uC. Sera samples (1:100 diluted) were added to the wells and the
plates were incubated overnight at 4uC. After washing the wells,
HRP labeled mouse anti-human IgG was added (1:5000) and
incubated further for 1 hr at 37uC. Color was developed using
OPD (o-phenylenediamine dihydrochloride) substrate. Absor-
bance was measured at 450 nm in a microplate reader (Bio-
Rad, Hercules, CA). We also determined the isotype of IgG
antibodies against rBmHsp12.6 and its peptides (N-BmHsp12.6
and BmHsp12.6ac) in the sera of subjects using an isotype specific
ELISA. Biotinylated mouse monoclonal anti-human IgG1, IgG2,
IgG3 and IgG4 were used as the secondary antibodies and color
was developed with avidin-HRP conjugate (Sigma) as the
secondary antibodies.
Antigen-specific proliferation of human peripheral blood
mononuclear cells
Peripheral blood mononuclear cells (PBMC) were isolated from
the heparinized venous blood of study subjects using histopaque
1077 column (Sigma). Viability of the cells was determined by
tryphan blue dye exclusion method. PBMC were then cultured in
96 well tissue culture plates at a concentration of 2610
5 cells/well
in RPMI 1640 supplemented with 10% FCS. PBMC were
stimulated either with rBmHsp12.6 antigen or non-specific
recombinant protein (rSmGBF) or ConA (1 mg/ml) or with
medium alone (unstimulated) in triplicate wells. PBMC were
stimulated in triplicate wells and the plates were incubated at 37uC
in 5% CO2. 72 h after incubation, cell proliferation was measured
by an MTT assay (Cell Titer 96 R aqueous non-radioactive cell
proliferation assay, Promega, Madison, WI). Stimulation index
was calculated and the results were expressed as Mean S.I 6 S.D.
Cytokine assay
Levels of Interferon-c (IFN-c), Interleukin-4 (IL-4) and Interleu-
kin-10 (IL-10) in the culture supernatants of PBMC stimulated
above with rBmHsp12.6 were estimated using Cytokine ELISA kits
(E-biosciences, San Diego, CA) as per the manufacturer’s instruc-
tion. Concentration of each cytokine in the culture supernatant was
plotted from a standard curve using recombinant IFN-c, rIL-4 or
rIL-10 and the data was expressed as pg/ml. Cytokine values in the
culture supernatant of control cells incubated with rSmGBF or
media alone was used as the background value.
Cloning of Codon optimized BmHsp12.6 into pVAX
vector for DNA vaccine
Codon optimized BmHsp12.6 genes encoding N-BmHsp12.6,
BmHsp12.6ac or full length BmHsp12.6 protein were cloned into
eukaryotic expression vector pVAX (Invitrogen, Carlsbad, CA)
using insert specific primers (forward primer: for N-BmHsp12.6;5 9-
CGCGGATCCATGGAG GAGAAGGTGG-39, for BmHsp12.6ac;
59-CGCGGATCCATGGTCATTCACTGCAGG-39 and for
BmHsp12.6;5 9-CGCGGATCCATGGAAGAGAAGGTGGTG-
39) containing BamHI site and (reverse primer: for N-BmHsp12.6;
59-CCGGAATTCTCAGGCTTTCTTCTTGGC-39, for BmHsp12.6ac;
59-CCGGAATTCTCACTTGGCAGCGATGA-39 and BmHsp12.6;
59-CCGGAA TT CTCACTTGTCGTTGGTG-39) containing
EcoRI site. PCR parameters were as follows: 94uC of denaturation
for 30 s, 50uC of primer annealing for 30 s, 72uC of primer
extension for 30 s for 30 cycles; a final extension of 5 min was
performed at 72uC. Insert DNA was sequenced to ensure
authenticity of the cloned nucleotide sequence on both strands.
Plasmids were maintained and propagated in E. coli Top10F9 cells.
Vaccine Potential of BmHSP12.6
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extraction kit (Qiagen, Hilden, Germany). DNA was analyzed by
agarose gel electrophoresis and quantified by spectrophotometry
(OD 260/280, ratio.1.8).
Immunization of mice
Six-weeks old male Balb/c mice purchased from Charles River
Laboratories were used in these experiments and divided into 8
groups. Each group consisted of five (5) mice and all mice were
immunized intraperitonealy (i.p). For DNA immunization, mice
were injected with four doses of 100 mg of pVAX N-BmHsp12.6
DNA or pVAX BmHsp12.6ac DNA or pVAX BmHsp12.6 DNA. For
recombinant protein immunization mice were injected with four
doses of 15 mg of rBmHsp12.6. For prime boost immunization,
mice were primed twice with 100 mg of pVAX N-BmHsp12.6 DNA
or pVAX BmHsp12.6ac DNA or pVAX BmHsp12.6 DNA and
followed by two booster doses of 15 mg of N-BmHsp12.6 peptide
or BmHsp12.6ac peptide or rBmHsp12.6 protein respectively.
Alum was used as an adjuvant for rBmHsp12.6. However,
synthetic peptide vaccines, despite being pure antigens, tend to be
poorly immunogenic when administered with alum [30]. There-
fore, saponin (0.2% w/v) was used as an adjuvant for N-
BmHsp12.6 and BmHsp12.6ac peptides. Saponin has been used
as an adjuvant with a variety of antigens, because it can enhance
immune responses to subunit vaccines in laboratory animals [31]
and humans [32]. Control animals received 100 mg of pVAX
vector alone and/or equal volumes of respective adjuvants at the
same interval. Blood samples were collected from each mouse
before immunization and one month after the last booster dose
and sera separated. Pooled sera of immunized mice containing
antibodies against rBmHsp12.6, N-BmHsp12.6 peptide and
BmHsp12.6ac peptide was used in neutralization assays.
Anti-BmHsp12.6 antibody levels in the sera of mice
Levels of anti-BmHsp12.6 IgG antibody in the sera (1:100) were
determined using an indirect ELISA as described previously [5].
IgG1, IgG2a, IgG2b and IgG3 anti-BmHsp12.6 antibody levels
were also determined using a mouse antibody isotyping ELISA kit
(ThermoFisher Scientific). Color was developed with OPD
chromogen substrate and the absorbance was measured at
450 nm in an ELISA reader (BioRad). Sera that showed high
titer of IgG antibodies were used in the Antibody Dependent
Cellular Cytotoxicity assay described below.
Antibody-dependant cellular cytotoxicity (ADCC) assay
In vitro ADCC assay was performed as described previously
[33,5]. Briefly, ten (10) L3 of B. malayi were incubated with 2610
5
peritoneal cells (PEC) collected from normal mice, 50 ml of pooled
mouse sera samples and 50 ml of RPMI 1640 media in a 96 well
culture plate (Thermo Fisher Scientific). After 48 h of incubation
at 37uC and 5% CO2, larval viability was determined at 4006
using a light microscope. Larvae that were limpid and damage
were counted as dead. In addition, dead larvae also had clumps of
cells adhered to it and were more transparent than live ones.
Larvae that were active coiled and translucent were counted as
live. ADCC was estimated as the percent larval death calculated
using the formula:
Number of Dead larvae7Total number of larvae|100:
ADCC assay was also performed with pooled human sera
samples as described above except that the human sera samples
were incubated with 2610
5 PBMC collected from normal healthy
subjects and 6–12 B. malayi L3 for 48 h at 37uC and 5% CO2.
Larval viability and death was determined as described above.
Depletion of anti-BmHsp12.6 antibodies from human
sera
BmHsp12.6 specific antibodies were depleted from the pooled
sera of EN subjects by passing through cobalt IMAC resin column
coupled with his-tagged rBmHsp12.6 as described by Veerapa-
thran et al. [5]. Briefly, 1 mg of his-tagged rBmHsp12.6 was
coupled to 2 ml bed volume of IMAC resin for 2 hrs at 37uC.
After washing the resin once with 10 ml of PBS (pH.8), 200 mlo f
pooled sera was added and incubated overnight at 4uC. After
incubation, the resin mixture was centrifuged for 2 min at
750 rpm and the supernatant was collected. Depletion of anti-
BmHsp12.6 antibodies in the supernatant was confirmed by an
ELISA as described above (Data not shown). Anti-BmHsp12.6
antibodies depleted sera sample was then used in an ADCC assay.
Evaluation of vaccine-induced protection in mice
Vaccine potential of BmHsp12.6 or its peptides were evaluated
using a mouse model of challenge infection. Mice were immunized
as described above and one month after the last immunization, a
micropore chamber containing challenge L3 was implanted into
the peritoneal cavity of mice as described by Abraham et al. [34].
Briefly, micropore chambers were assembled using 1462m m
plexi rings (Millipore Corporations, Bedford, MA) and 5.0 mm
nucleopore polycarbonate membranes (Millipore Corporations).
The membranes were attached to the plexi glass rings with
cynoacrylic adhesive and dental cement. The chambers were
immersed overnight at 37uC in sterile RPMI medium containing
gentamycin and antimycotic solution. Before the challenge
experiments, 20 live infective L3 suspended in RPMI1640
medium supplemented with 10% heat inactivated fetal bovine
serum (FBS), were introduced into the micropore chambers and
the opening was sealed with dental cement. Micropore chamber
containing L3 were then surgically implanted into the peritoneal
cavity of each mouse under anesthesia. Aseptic conditions were
followed for the surgical procedures. After 48 h of implantation,
animals were sacrificed and the chambers were recovered from the
peritoneal cavity. Contents of each chamber were emptied and
larvae were examined microscopically for adherence of cells and
for larval death. Dead and live larvae were identified as described
above under ADCC. The percentage of larval death was expressed
as the number of dead parasites/number of total parasites
recovered6100.
Splenocytes proliferation assay
Spleens were collected from all mice from the above experiment
and single cell suspension of spleen cells was prepared. Approxi-
mately 2610
5 cells/well suspended in complete RPMI1640
medium supplemented with 10% heat inactivated FBS were
incubated at 37uC and 5% CO2 for 72 hrs with either 1 mg/ml of
antigens (rBmHsp12.6, N-BmHsp12.6 peptides or BmHsp12.6ac
peptides) or non filarial recombinant protein (rGBF) or ConA or
with medium alone. After incubation, cell proliferation was
determined using cell counting kit (CCK-8) purchased from
Dojindo Molecular Technologies, Inc, Gaithersburg. Stimulation
index of spleen cell proliferation was calculated using the formula:
Absorbance of stimulated cells4Absorbance of unstimulated cells.
Statistical Analysis
Statistical analysis was performed using GraphPad prism
software version 5. Comparisons between two individual data
Vaccine Potential of BmHSP12.6
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non-parametric Kruskal–Wallis test was used. Statistical signifi-
cance level was set at p,0.05.
Results
BmHsp12.6 has an alpha-crystalline domain
Secondary structure prediction analysis of BmHsp12.6 protein
showed the presence of an alpha-crystalline domain that has an
immunoglobulin core consisting of seven b-strands arranged in
two anti-parallel sheets (Figure 1A). The secondary structure
prediction also showed that the N- terminus fragment (aa 1–30)
has no predicted secondary structure.
HuIL-10R binding region of BmHsp12.6 resides within the
N-BmHsp12.6 sequences
Previous studies showed that BmHsp12.6 binds to human IL-10
receptor I a chain [19]. To identify the IL-10 receptor binding site
on BmHsp12.6, we performed a predictive protein-protein
interaction analysis as described previously [35]. Results from
the prediction analysis showed that the N-BmHsp12.6 (amino
acids from Met
1 to Asn
26) has a strong protein-protein interaction
region. Further sequence analysis of this region showed that the
amino acid sequence from Val
5 to Glu
42 has 16% sequence
identity and 38% similarity to human IL-10R binding region of
human IL-10. These findings suggest that the N-BmHsp12.6 may
be involved in the binding of BmHsp12.6 to human IL-10 receptor
I a chain.
BmHsp12.6 protein has similar motifs as human IL-10
Motif analysis performed at the PROSITE showed several
putative post-translation modification sites such as N-glycosylation
sites (aa 11 to 14 and 98 to 101), protein kinase-c phosphorylation
sites (aa 83 to 85 and 100 to 102), casein kinase II phosphorylation
sites (aa 68 to 71 and 88 to 91) and N-myristylation sites (aa 40 to
45) on BmHsp12.6. Similar motifs were also observed in human
IL-10 further confirming the previous findings that BmHsp12.6
may mimic human IL-10 function [10].
N-BmHsp12.6 contains IL-10R binding site and
BmHsp12.6ac has immunogenic epitopes
Analysis of the BmHsp12.6 sequences showed that the
sequences from aa 1–36 had IL-10R binding region. This region
was termed N-BmHsp12.6 peptide as this resides in the N-
terminus region of BmHsp12.6. Epitope analysis showed that
sequences from aa 61–113 contained linear B epitopes, T epitopes
and CTL epitopes (Table 1). This region was termed
BmHsp12.6ac peptide and is graphically represented in Figure 1B.
N-BmHsp12.6 promotes MC/9 mast cell proliferation
In vitro function studies using MC/9 cells showed that when
MC/9 cells were incubated with N-BmHsp12.6 peptide
(Figure 2A) they proliferated nearly at the same level as with
rBmHsp12.6 or rhuIL-10 (Figure 2B). The MC/9 growth
stimulating activity of N-BmHsp12.6 peptide or rBmHsp12.6
were abolished when pooled mouse sera containing polyclonal
antibodies against N-BmHsp12.6 peptide or rBmHsp12.6 were
added to the cultures suggesting that the effect of N-BmHsp12.6
peptides and rBmHsp12.6 on MC/9 is specific. No inhibitory
effect was observed when control sera were used with N-
BmHsp12.6 peptide or rBmHsp12.6. Similarly, MC/9 cells
cultured in the presence of BmHsp12.6ac peptide showed no
significant proliferation compared to controls (Figure 2C). These
results suggest that the IL-10R binding N-BmHsp12.6 also has IL-
10-like function in vitro on MC/9 cells.
BmHsp12.6 is a chaperone
Majority of the heat shock proteins reported to date have
chaperone function. To test if BmHsp12.6 also has similar
chaperone function, we performed a thermal aggregation reaction
using Citrulline synthase (CS) as a substrate. Incubation of CS at
45uC resulted in unfolding of the protein and subsequent
Figure 1. Structural analysis of BmHsp12.6. (A) Secondary structure prediction of BmHsp12.6 showing a-helices (H1 and H2), strands by their
sheets A, B, (b)- beta turn, (c)- gamma turn and beta hairpin ()). (B) Graphical representation showing N-BmHsp12.6 and BmHsp12.6ac peptide
sequences and their functional roles in the BmHsp12.6 protein.
doi:10.1371/journal.pone.0034077.g001
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rBmHsp12.6 to CS protein (at a molar ratio of 1:2) before the
heat treatment significantly (P,0.01) inhibited the thermal
aggregation of CS protein (Figure 3). Addition of a non-chaperone
control protein, BSA to CS had no effect on the heat-induced
aggregation of CS protein.
Another key function of chaperone proteins is that they can
specifically bind to denatured proteins. To test if BmHsp12.6 can
specifically bind to denatured proteins, we incubated rBmHsp12.6
with CS protein or luciferase (native and denatured) proteins.
These studies showed that rBmHsp12.6 preferentially binds to
denatured protein compared to native or control proteins
(Figure 3B). These findings further confirmed that BmHsp12.6
can act as a molecular chaperone potentially protecting the
parasite cellular proteins from the damaging effects of the host.
EN subjects carry high levels of circulating anti-
BmHsp12.6 antibodies
Epitope mapping on BmHsp12.6 revealed the presence of B-
cell, T-cell and CTL epitope regions in the protein (Table 1)
suggesting that BmHsp12.6 is potentially a highly immunogenic
peptide. Therefore, we assumed that filariasis infected individuals
might carry antibodies to BmHsp12.6. Analysis of the titer of IgG
antibodies against BmHsp12.6 and its subunits in the sera of EN,
CP, MF and NEN subjects showed that the EN subjects had the
highest levels of anti-BmHsp12.6 (Figure 4A) or anti
BmHsp12.6ac (Figure 4B) antibodies (p,0.001) in their sera.
EN subjects did not carry any IgG antibodies against the N-
BmHsp12.6 peptides (Figure 4C). Subsequent isotype analysis of
the IgG anti-BmHsp12.6 or anti BmHsp12.6ac antibodies showed
that IgG1 and IgG3 anti-BmHsp12.6 antibodies were the most
predominant antibodies in the sera of EN subjects (Figure 5). Anti-
BmHsp12.6 antibodies in the sera of MF carriers were mainly of
IgG2 and IgG4 isotype, whereas, anti-BmHsp12.6 antibodies in
the sera of CP individuals were predominantly IgG4 isotype.
Levels of both IgG1 and IgG3 isotype of anti-BmHsp12.6
antibodies were low or near background level in the sera of MF
and CP individuals. Anti-BmHsp12.6ac antibodies in the sera of
CP patients carried predominantly IgG4 isotype antibodies. Levels
of IgG1, IgG2 and IgG3 isotype of anti-BmHsp12.6ac antibodies
were very low in MF individuals. No anti-BmHsp12.6 or anti-
BmHsp12.6ac antibodies could be detected in the sera of NEN
subjects.
Anti-BmHsp12.6 antibodies in the sera of EN subjects are
involved in ADCC mediated protection
Above results show that antibodies to BmHsp12.6 were present
in the sera of infected groups of individuals (MF and CP) and in
putatively immune EN subjects. To test if these antibodies are
functional, we performed an in vitro antibody dependent cellular
cytotoxicity assay, where the respective serum (antibodies) is
combined with PBMC from a healthy donor and ability of the
antibodies to participate in larval killing is evaluated. Results of the
ADCC assay show that pooled sera from EN subjects (N=10)
promoted adherence of PBMC to the surface of L3 and caused
significant (P,0.05) death of B. malayi L3 in vitro (Table 2),
whereas, pooled sera from MF, CP or NEN failed to induce cell
adherence or larval killing (Table 2). To further determine the role
of anti-BmHsp12.6 antibodies in this larval killing, we depleted
anti-BmHsp12.6 antibodies from the pooled sera of EN subjects
and used it in the ADCC assay above. Results show that depletion
of anti-BmHsp12.6 antibodies from the sera samples significantly
(P,0.05) impaired their ability to participate in the killing of L3
(36%) suggesting that the anti-BmHsp12.6 IgG1 and IgG3
antibodies in the sera of EN subjects may have a role in the
killing of L3.
BmHsp12.6-specific cells are present in EN subjects
Freshly isolated PBMC from different filarial groups (EN, MF
and CP, n=10) were stimulated with rBmHsp12.6 or ConA and
proliferative response was measured using an MTT assay. Figure 6
show that PBMC from EN individuals stimulated with
rBmHsp12.6 (S.I. 1.6–2.6) showed significant proliferative re-
sponses (p,0.05) compared to PBMC from CP individuals (S.I.
0.8–2.1) and MF individuals (S.I. 0.8–1.0). Control wells
stimulated with ConA showed S.I. 1.8–3.7 for EN; S.I. 0.9–3.8
for CP and S.I. 0.7–3.1 for MF.
BmHsp12.6 specific cells in EN subjects predominantly
secrete IFN-c
Levels of IFN-c, IL-4 and IL-10 were estimated in the cultures
supernatants of PBMC stimulated with rBmHsp12.6. Results
showed that rBmHsp12.6 induced secretion of significant levels
(193.7 pg/ml) of IFN-c (p,0.001) from the PBMC of EN subjects
compared to PBMC from MF and CP individuals (Figure 7).
Levels of IL-4 and IL-10 were also slightly increased (27.2 and
98.4 pg/ml respectively) in the culture supernatant of PBMC from
EN subjects stimulated with rBmHsp12.6. PBMC from MF
subjects secreted significant amounts of IL-10 in response to
rBmHsp12.6 and PBMC from CP individuals showed slight
increases in IFN-c but not as significant as the EN subjects. There
were no detectable levels of cytokine in the culture supernatants of
control PBMC from EN subjects incubated in the media (data not
shown).
BmHsp12.6 and BmHsp12.6ac is a potential vaccine
candidate
Above results show that putatively immune EN subjects carry
antibodies against rBmHsp12.6 is involved ADCC mediated
protection. Therefore, to test if rBmHsp12.6 or its peptides (N-
BmHsp12.6 and BmHsp12.6ac) has any vaccine potential; we
performed a proof-of-concept vaccine trial in Balb/c mice using a
Table 1. Predicted B-cell, T-cell and CTL epitopes in
BmHsp12.6 sequences.
Epitopes predicted
a
Position of epitope in
the aa sequence Peptide sequence
B-cell epitopes 67–74 SRAEHYGE
87–101 PSDVDTKTLTSNLT
T-cell epitopes 50–57 IEVKVAGD
52–60 VKVAGDNLV
84–92 KLPSDVDTK
92–100 KTLTSNLTK
90–98 DTKTLTSNL
100–108 KRGHLVIAA
73–81 GEIKREISR
CTL epitopes 78–86 REISRTYKL
74–82 GEIKREISR
70–78 AEHYGEIKR
aImmune Epitope Database and Analysis Resource (IEDB) was used for the
prediction.
doi:10.1371/journal.pone.0034077.t001
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also immunized one group of mice with rBmHsp12.6 protein.
These studies showed that all immunized mice developed
significant levels of anti-BmHsp12.6 IgG antibodies (Figure 8).
Overall, rBmHsp12.6 protein vaccination gave the highest titer of
IgG antibodies (p,0.05) compared to DNA vaccination
(Figure 8A). The DNA prime protein boost vaccination regimen
also elicited a strong IgG response however the titer was
significantly lower than the protein alone vaccination group. Titer
of IgG antibodies after prime boost vaccination with
BmHsp12.6ac peptide was comparable to those after vaccination
with rBmHsp12.6 (Figure 8B). N-BmHsp12.6 peptide was a poor
immunogen either as a DNA vaccine or with prime boost
vaccination (Figure 8C).
Analysis of the isotype of anti-BmHsp12.6 IgG antibodies in
BmHsp12.6 vaccinated mice showed that predominantly IgG1,
IgG2a and IgG2b anti-BmHsp12.6 antibodies were present in the
sera of these animals (Figure 9A). IgG1 and IgG2a antibodies were
also increased in the sera of rBmHsp12.6ac vaccinated animals
(Figure 9B). However, in N-BmHsp12.6 vaccinated animals, there
was no significant increase in any IgG isotype of antibodies
(Figure 9C).
Vaccination with BmHsp12.6 and BmHsp12.6ac confers
significant protection in mice
Above results showed that significant antibodies are generated
in the sera of vaccinated mice. To test if these antibodies can
confer protection, we performed an in vitro ADCC assay similar to
Figure 2. MC/9 proliferation assay. N-BmHsp12.6 peptide enhances the growth of MC/9 mast cells in vitro. The effects of different peptides of
BmHsp12.6 on MC/9 cells were determined by a cell viability assay. 5610
3 cells/ml of MC/9 were stimulated with 10 mg/ml of A) N- BmHsp12.6 B)
BmHsp12.6 and C) BmHsp12.6ac (10 mg/ml) for 72 h at 37uC. Sera containing antibodies against the respective proteins were added to certain
cultures. Sera samples from normal Balb/c mice served as negative controls. Cells stimulated with rhuIL-10 (100 ng/ml) served as positive control.
Data presented is representative of one of three similar experiments. * Significant (p,0.005) compared to all the other groups.
doi:10.1371/journal.pone.0034077.g002
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antibodies from rBmHsp12.6 and BmHsp12.6ac peptide vacci-
nated mice promoted adherence of peritoneal exudate cells to L3
and participated in larval killing in vitro (83% or 81% respectively)
compared to sera from control animals (13%), significant p,0.01
(Table 3). However, sera from N-BmHsp12.6 peptide vaccinated
mice were less efficient in killing L3 (43%). These findings
confirmed that IgG antibodies present in the sera of rBmHsp12.6
and BmHsp12.6ac vaccinated mice are participated in ADCC
mediated killing.
Vaccine potential of rBmHsp12.6 and BmHsp12.6ac was
further confirmed in the mouse model using a micropore chamber
challenge method. Results showed that 72%, 83% and 38% larval
death occurred in mice vaccinated with rBmHsp12.6,
BmHsp12.6ac or N-BmHsp12.6 protein respectively compared
to 7% larval death in controls (Table 3). These findings confirmed
that vaccination with both BmHsp12.6ac and rBmHsp12.6
induced significant (P,0.01) protection and were comparable to
the ADCC results and human PBMC assays, whereas, mice
immunized with N-BmHsp12.6 peptide was not as efficient as the
other two proteins. Following DNA vaccination, the larval death
were 31%, 63% and 31% in mice vaccinated with BmHsp12.6,
BmHsp12.6ac or N-BmHsp12.6 DNA respectively suggesting that
vaccination with BmHsp12.6ac DNA is significantly better than
BmHsp12.6 and N-BmHsp12.6. Our results show that prime boost
vaccination regimen with BmHsp12.6 and BmHsp12.6ac is highly
efficient in conferring vaccine-induced protection against the
challenge infection.
Spleen cells from vaccinated animals showed antigen
specific recall response
Spleen cells from animals immunized with rBmHsp12.6
(Figure 10A) and BmHsp12.6ac (Figure 10B) and using a prime-
boost regimen proliferated significantly (P,0.001) in response to
the respective recombinant antigen (SI of 3.4360.410 and
4.3560.415). However, spleen cells from N-BmHsp12.6 immu-
nized animals (SI of 1.3060.434) did not proliferate well in
response to N-BmHsp12.6 peptide (Figure 10C). Stimulation
index of splenocytes from pVAX BmHsp12.6 DNA vaccinated
group (SI of 3.1860.565) showed significant proliferation than
splenocytes from pVAX N-BmHsp12.6 DNA (SI of 1.6060.342) or
pVAX BmHsp12.6ac DNA (SI of 1.9960.481) vaccinated animals.
Spleen cells from control group of animals failed to proliferate in
response to any of the antigens tested (SI 1.46–1.560.13–0.15)
and was similar to media alone controls.
Discussion
Experiments described in this manuscript show that B. malayi
HSP12.6 (BmHsp12.6) is structurally and functionally similar to
other members of the class of small heat shock proteins that can
act as molecular chaperones. The small heat shock proteins can
recognize proteins of non-native structure and prevent them from
irreversible intracellular aggregation [36]. Our results showed that
BmHsp12.6 can bind to cellular proteins and protect them from
heat aggregation or chemical denaturation. These functions may
be critical for survival of the parasite in the vertebrate host. Our
previous studies reported that BmHsp12.6 can bind to human IL-
10R and activate IL-10 mediated effects in vitro [10]. In the present
study we show that the IL-10R binding region of BmHsp12.6
resides in its N-terminal sequences. Based on this finding it was
predicted that BmHsp12.6 has host immunomodulatory function.
Thus, neutralizing the effects of BmHsp12.6 might interfere with
the establishment of the infective stages of the parasite in the host.
Therefore, in this manuscript we evaluated the vaccine potential of
BmHsp12.6. Our results show mice vaccinated with rBmHsp12.6
using a heterologous prime boost approach exhibit close to 72%
protection against a challenge infection. The a-crystalline domain
and C-terminal extension of BmHsp12.6 (BmHsp12.6ac) were
Figure 3. Recombinant BmHsp12.6 prevents thermal aggregation of proteins. (A) Citrulline synthase (CS) were heat denatured at 45uCi n
the presence and absence of rBmHsp12.6 at different time intervals (0–40 min). BSA served as control. Thermal aggregation of proteins was
determined spectrophotometrically by measuring the light scatter at 300 nm. Results show that ratio of CS: BmHsp12.6 (1:2) was sufficient to prevent
thermal aggregation of CS. Data presented are representative of three similar experiments. (B). BmHsp12.6 can bind to denatured proteins.
Binding of rBmHsp12.6 to denatured Citruline synthase (CS) and luciferase (LUC) was determined using an ELISA. CS or luciferase was denatured with
6 M guanidium hydrochloride overnight at 4uC. Wells of 96 wells plate was then coated with the denatured or native CS or LUC and binding of his-
tag rBmHsp12.6 or control filarial protein to the coated proteins (CS and LUC) was then analyzed using HRP-labeled penta- his antibodies by ELISA.
Results show that BmHsp12.6 preferentially binds to denatured proteins. * Significant (p,0.005) binding of BmHsp12.6 to denatured proteins
compared to control and native proteins.
doi:10.1371/journal.pone.0034077.g003
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correlated with our subsequent findings that majority of the
vaccine-induced protection conferred by BmHsp12.6 is associated
with BmHsp12.6ac.
Structural analysis of BmHsp12.6 showed that the N-terminal
region of BmHsp12.6 has no specific structures. Interestingly,
similar intrinsically disordered regions have been described from
other small heat shock proteins that can interact with diverse
geometries of hydrophobic patches on unfolding proteins [37,38].
A considerable body of evidence suggests that these intrinsically
unstructured regions of proteins play key roles in protein–protein
interactions [38,39]. In fact, the BmHsp12.6ac peptide can only
bind with lower intensity to the substrates compared to the
intrinsically unstructured N-terminal arm [40]. Thus, the N-
terminal arm of BmHsp12.6 appear to be the most favored site for
protein-protein interaction and possibly the contact region for
potential substrates. At present we do not know if this region is
critical for the chaperone function of BmHsp12.6. However, we
now know that the N-terminal arm of BmHsp12.6 is involved in
the binding of BmHsp12.6 to huIL-10 receptor by in silico analysis.
Extensive sequence analysis of the N-terminus region of
BmHsp12.6 showed the presence of similar motifs in both
BmHsp12.6 and huIL-10. Since protein motifs are signatures of
protein families and can often be used as tools for the prediction of
protein function, presence of similar motifs in both the IL-10 and
BmHsp12.6 suggests that both these proteins may share similar
functions. One of these functions appears to be binding to IL-10R.
This was further confirmed by the fact that binding of
rBmHsp12.6 to huIL-10R interferes with the binding of huIL-10
to huIL-10R suggesting that both proteins may share similar
binding sites on huIL-10R. Reinke et al.1998 [41], identified the
IL-10/IL-10R combining site by mapping sets of overlapping
peptides derived from both binding partners. When the sequence
of this binding site was compared to BmHsp12.6 sequences, we
found that the N-terminal arm of BmHsp12.6 has identical amino
acid sequence to the IL-10R binding peptide of huIL-10.
Subsequently, we prepared N-BmHsp12.6 peptide and when
tested on MC/9 cells in vitro these cells proliferated similar to those
induced by rhuIL-10 and full length BmHsp12.6. However,
BmHsp12.6ac failed to bind to huIL-10R and failed to stimulate
MC/9 cells. These observations strongly suggest that N- terminal
sequence of BmHsp12.6 is involved in the binding of BmHsp12.6
to huIL-10R. Similarly the IL-10 like function of BmHsp12.6 also
was found to be associated with the N-BmHsp12.6 peptide.
Lymphatic filarial parasites are notorious for suppressing host
immune responses by inducing an IL-10 response [42]. Thus, it is
possible that the N-terminal arm of BmHsp12.6 may have a
significant role in the host immune modulatory function.
Neutralizing the effects of this protein can have significant host
benefit. Further studies using N-BmHsp12.6 peptide are necessary
to understand the mechanism of host immunomodulation by this
peptide.
Figure 4. Anti-rBmHsp12.6 IgG antibody levels in the sera of human. Levels of total IgG antibodies against (A) rBmHsp12.6 protein, (B)
BmHsp12.6ac peptide or (C) N-BmHsp12.6 peptide in the sera of EN, MF, CP and NEN subjects were measured using an indirect ELISA. A total of 20
sera samples were evaluated from EN, MF, and CP and 10 samples from NEN. Each data point represents sera sample from a single individual.
Horizontal lines represent geometric mean value. Data is represented as scatter plot where each dot represents absorbance of individual sera.
doi:10.1371/journal.pone.0034077.g004
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excellent vaccine candidates. For example, vaccination of mice
with T. gondii HSP30 gene, a member of the sHSP family, induced
significant protection against challenge infections [43]. Similarly,
DNA vaccine encoding hsp60 gene was protective against M.
tuberculosis in infected mice [44]. Small HSPs also appear to be
critical for the survival of the parasite. Over expression of small
HSPs in C. elegans confer increased lifespan [12,45]. Similarly,
BmHsp12.6 homologue in Nippostrongulus braziliensis (Nb-Hsp12.6)
was shown to be involved in the survival strategies of the parasitic
nematodes in deleterious environmental conditions both outside
and inside the host [46]. These findings suggest that BmHsp12.6
may be an important survival protein in the parasite. Therefore
neutralizing the effect of BmHsp12.6 can have deleterious effect
on the parasite.
We measured the titer and isotype of IgG antibodies against
BmHsp12.6 and its peptides in the sera of human subjects. These
results showed that putatively immune individuals (EN) carry IgG
antibodies against BmHsp12.6 and BmHsp12.6ac subunit but not
to N-BmHsp12.6 subunit. This finding showed that BmHsp12.6ac
is highly immunogenic in the human host. Epitope analysis of
BmHsp12.6 further confirmed this. Depletion of anti-BmHsp12.6
antibodies from the human sera samples significantly reduced the
larval killing activity of the sera in ADCC assay suggesting that the
antibodies generated against BmHsp12.6 or BmHsp12.6ac
peptide may be involved in the protection. Several previous
studies show that antibodies play a major role in the protection
against lymphatic filariasis [47,48,49]. More specifically these
antibodies target infective L3, which can be measured in vitro using
an ADCC assay. In fact ADCC is believed to be one of the
principal immunological mechanisms responsible for the clearance
of circulating lymphatic filarial parasites in both immune human
Figure 5. Anti-rBmHsp12.6 IgG antibody isotypes in the human sera. IgG isotype antibodies against (A) rBmHsp12.6 protein, (B)
BmHsp12.6ac peptide or (C) N-BmHsp12.6 in the sera of EN, MF, CP and NEN subjects were measured using an indirect ELISA. A total of 20 sera
samples were evaluated from EN, MF, and CP from NEN. Each data point represents sera sample from a single individual. Each bar represents the
mean 6 SD of five patients from each group. * Significant (p,0.05) compared to all the other three groups (CP, MF and NEN).
doi:10.1371/journal.pone.0034077.g005
Table 2. Antibody-dependant cellular cytotoxicity (ADCC)
against B. malayi L3 using human serum.
Groups % Larval death
a (Mean ± SD)
Endemic normal (EN) sera 75±11.85*
EN sera depleted of anti rBmHsp12.6
antibodies
36613.82
Non endemic normal (NEN) sera 1465.90
Microfilaremic (MF) sera 665.5
Chronic pathology (CP) sera 968.4
a50 ml of pooled EN, NEN, MF or CP human sera (n=10) samples were
incubated with 2610
5 normal PBMC and B. malayi L3 at 37uC for 48 hrs.
Following incubation, larval viability was determined and percent larval death
was calculated. Anti-BmHsp12.6 antibodies were depleted from the EN pooled
sera by passing through an affinity column containing immobilized BmHsp12.6.
Depleted sera samples are then used in ADCC assay. Values represent mean 6
SD of three wells.
*Significant larval death (P,0.005) compared to NEN, MF and CP sera samples.
doi:10.1371/journal.pone.0034077.t002
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measure protection in human. MF and CP individuals also carried
antibodies against BmHsp12.6 in their sera. However, these
antibodies were mostly IgG2 and IgG4 isotype. Use of these sera
in ADCC assay was not effective in killing B. malayi L3. Anti-
BmHsp12.6 and anti-BmHsp12.6ac peptide antibodies present in
the sera of EN subjects were predominantly cryophilic IgG1 and
IgG3 antibodies. Other studies have also reported similar antibody
responses that are protective in EN subjects [3,50–52].
Our results showed that in addition to the significant antibody
responses, the PBMC from EN subjects showed significant recall
responses to rBmHsp12.6 antigen in vitro suggesting that
BmHsp12.6-specific memory cells are present in the circulation of
EN subjects. Others have also reported the presence of B. malayi or
W. bancrofti-specific circulating memory cells in EN subjects
suggesting that these groups of individuals are immunologically
highly responsive against B. malayi antigens and parasites [52,53].
BmHsp12.6 antigen-responding cells predominantly secreted IFN-c
Figure 6. Proliferation of human PBMC stimulated with rBmHsp12.6. PBMC proliferation of (A) Endemic Normal (EN), (B) Microfilaraemic
(MF) and (C) Chronic Pathology (CP) groups stimulated with rBmHsp12.6. Concanavalin A (ConA) was used as a positive control. Each data point
represents stimulation index (S.I) of individual human sample (n=10).
doi:10.1371/journal.pone.0034077.g006
Figure 7. Cytokine levels in human PBMC. Cytokines (pg/ml) in
the culture supernatants of human PBMC were measured using an
ELISA. Results show that significant level of IFN-c is secreted by PBMC of
EN individuals in response to rBmHsp12.6. Experiments were repeated
two times. Each bar represents mean concentration 6 S.D. * Significant
(p,0.05) IFN-c secretions compared to other two groups (CP and MF).
doi:10.1371/journal.pone.0034077.g007
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BmHsp12.6 mediated protection in human. This assumption largely
based on our finding that anti-BmHsp12.6 antibodies involved in
killing of L3 in vitro in the ADCC assay. Similar correlation of IgG1
production with Th1 and inflammatory responses was observed in
TB [54]. In fact we found that the anti-BmHsp12.6 antibodies were
largelyof the IgG1isotype.Thus,there isa clearcorrelation between
the cellular response and antibody response elicited against
BmHsp12.6 antigen in EN subjects. Since the anti-BmHsp12.6
antibodies in the sera of EN subjects were involved in the protection
mediated by ADCC, we next wanted to determine the vaccine
potential of BmHsp12.6 in a mouse model.
Vaccination of mice with rBmHsp12.6 or BmHsp12.6ac was
found to induce significant IgG1 and IgG2a antibody responses.
Similarly, immunization of C-terminal domain of Plasmodium
falciparum HSP70 induced IgG2a antibody response in mice
models [55]. Mouse IgG2a antibodies are functionally similar to
human IgG1 antibodies [56], and mouse IgG1 antibodies are
functionally similar to human IgG4 antibodies. Thus the human
correlate of IgG antibody responses against BmHsp12.6 is at least
partially similar in the mouse. ADCC assay using sera from
vaccinated animals showed that similar to EN subjects, sera
samples from mouse vaccinated with rBmHsp12.6 or
BmHsp12.6ac was able to kill B. malayi L3 in vitro. However, sera
samples from mice immunized with N-BmHsp12.6 were unable to
promote killing of B. malayi L3 in ADCC. Lack of immunogenic
epitopes in N-BmHsp12.6 and the presence of IL-10R binding
region may be responsible for these poor responses. Similar results
were observed when mice were challenged with B. malayi L3 in the
micropore chamber, which is a more physiological milieu for
larval growth and survival and yet permits the analysis of host
effector mechanisms in vivo [57]. In mouse vaccinated with
rBmHsp12.6 or BmHsp12.6ac, we observed large number of cells
attached to the cuticle of the larvae inside the micropore chamber.
There was also significant larval death. Based on these findings we
believe that the cells that are attached to the larvae are critical for
the effector function as serum was not capable of killing the larvae
[5]. Further studies will identify the phenotype and mechanism of
effector cell mediated killing in this model.
In our mice studies significant enhancement of protection was
achieved against infective L3 when BmHsp12.6 was given as a
prime boost vaccination regimen. This is potentially because the
DNA vaccine can generate T cells with high affinity and the
recombinant protein vaccine can amplify the response [58]. DNA
vaccines have been developed against a wide range of pathogens
including S. mansoni [59], Mycobacteria [44], and Trypanosoma cruzi
[45]. DNA vaccination induces potent cellular responses. Howev-
er, one of the disadvantages of DNA vaccination is that the levels
of humoral immune responses generated is modest. Thus, DNA
vaccines may be good as priming agents in combination vaccines.
In the present study mice immunized with BmHsp12.6 DNA
vaccine alone gave only 32% protection which supports previous
Figure 8. Titer of IgG antibodies. Mice were immunized with A) BmHsp12.6, B) BmHsp12.6aco rC) N-BmHsp12.6 using homologous DNA vaccine
regimen or a heterologous prime boost approach. Approximately, 100 ng of peptides or proteins respectively (100 ng/100 ml/well) were coated on to
the wells of an ELISA plate and bound serum IgG was detected using an HRP-labeled anti-mouse IgG secondary antibody. Each data point indicates
mean (6 S.D) value from five animals.
doi:10.1371/journal.pone.0034077.g008
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of protection against parasitic infections [59]. Similarly, vaccina-
tion with rBmHsp12.6 protein alone could only confer 58%
protection against B. malayi infections. However, a combination of
BmHsp12.6 DNA prime and rBmHsp12.6 protein boost vaccina-
tion regimen synergistically gave 83% protection against a
challenge infection. Similar results have been reported with
other heterologous prime/boost vaccination approaches as well
[60,61].
In conclusion, in this study we show that the BmHsp12.6 has
significant chaperone activity and its IL-10R binding region was
mapped to N-terminal sequence of BmHsp12.6. Small HSPs have
been extensively tested as vaccine candidates against several
infectious agents and cancer. To demonstrate the vaccine potential
of BmHsp12.6, we first showed that putatively immune EN
subjects carry anti-BmHsp12.6 IgG1 and IgG3 antibodies in
their sera that can participate in the killing of B. malayi L3 in an
ADCC assay. Subsequent vaccination trial in a mouse model
showed that the BmHsp12.6 and BmHsp12.6ac subunit of
BmHsp12.6 gave significant protection in mice following a
heterologous prime boost regimen. These findings thus show that
the BmHsp12.6 can be further developed into a vaccine candidate
against B. malayi.
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Figure 9. Isotype of anti-BmHsp12.6 IgG antibodies in the sera of mice. Mice were immunized with A) BmHsp12.6, B) BmHsp12.6aco rC)N -
BmHsp12.6 using homologous DNA vaccine regimen or a heterologous prime boost approach. Control mice were immunized with vector alone or
adjuvant. Isotype specific ELISA was performed as described in the methods section. Bars represent mean O.D 6 SD from five mice per group.
* Significant (p,0.005) compared to all the other groups.
doi:10.1371/journal.pone.0034077.g009
Table 3. Killing of B. malayi L3 in rBmHSP12.6 vaccinated
mice was evaluated by in vitro (ADCC assay using mouse sera)
and in vivo (micropore chamber challenge) assays.
% larval death
Immunization regimen in vitro(ADCC)
a
in vivo (micropore
chamber)
b
N-BmHsp12.6 (prime boost) 43.9762.71 38614.8
pVAX N-BmHsp12.6 DNA 29.7663.92 3162.40
BmHsp12.6ac (prime boost) 81.58±1.68
* 83±5.72*
pVAX BmHsp12.6ac DNA 47.9461.34 6365.50
BmHsp12.6 (prime boost) 83.02±3.62* 72±10.22*
pVAX BmHsp12.6 DNA 43.768.12 3165.23
rBmHsp12.6 protein 55.0861.15 5867.76
Control 1362.35 765.2
aADCC assay was performed by incubating 50 ml of pooled mice sera (n=5)
samples with 2610
5 normal peritoneal exudates cells and 10 B. malayi L3 at
37uC for 48 hrs. Values represent mean 6 SD of three wells.
bIn vivo micropore chamber assay was performed by surgically implanting 20 B.
malayi L3 into the peritoneal cavity of each mouse. 48 hrs after implantation,
chambers were removed and larval viability and death determined. Values are
mean 6 SD. N=5. Data presented is from one of two similar experiments
showing comparable results.
*Significant larval death (P,0.01) compared to other mice groups.
doi:10.1371/journal.pone.0034077.t003
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